X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Enveric plans to continue to focus and invest in the development of its lead candidates EB-003, a first-in-class neuroplastogen designed to eliminate hallucinations, and EB-002, formerly EB-373, a next generation synthetic prodrug of the active metabolite, psilocin.
Lead Product(s): EB-003
Therapeutic Area: Psychiatry/Psychology Product Name: EB-003
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment January 23, 2024
Details:
EB-003 is a novel 5-HT2A receptor agonist which is currently being evaluated in preclinical studies for the treatment of depression and anxiety disorders.
Lead Product(s): EB-003
Therapeutic Area: Psychiatry/Psychology Product Name: EB-003
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
EB-373 (psilocybin prodrug) is an oral 5-HT2A receptor agonist. It is being evaluated in preclinical studies for the treatment of generalized anxiety disorder.
Lead Product(s): Psilocybin Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: EB-373
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2023
Details:
Enveric lead product candidate EVM301, which is a 5-HT2A receptor modulator small molecule drug candidate. It is being evaluated for the treatment of anxiety.
Lead Product(s): EVM301
Therapeutic Area: Psychiatry/Psychology Product Name: EVM301
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
EB-373, is a new chemical entity (NCE), designed as a next-generation proprietary psilocin prodrug and developed leveraging the company’s Psybrary™ drug discovery platform to target psychiatric disorders.
Lead Product(s): Psilocin Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: EB-373
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
EB-373, is a new chemical entity (NCE), designed as a next-generation proprietary psilocin prodrug and developed leveraging the company’s Psybrary™ drug discovery platform to target anxiety disorders.
Lead Product(s): Psilocin Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: EB-373
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
EB-373, is a New Chemical Entity (NCE), designed as a next-generation proprietary psilocin prodrug and developed leveraging the company’s Psybrary™ drug discovery platform to target anxiety disorders.
Lead Product(s): Psilocin Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: EB-373
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
EB-373 is a New Chemical Entity (NCE), designed as a next-generation proprietary psilocin prodrug and developed by leveraging its Psybrary™ drug discovery platform to target anxiety disorders.
Lead Product(s): Psilocybin Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: EB-373
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
EB-373 (psilocin prodrug) is a new chemical entity, designed as next-generation psilocin prodrug (serotonin 5-HT2A receptor inhibitor) and developed leveraging its psybrary™ drug discovery platform to target anxiety disorders.
Lead Product(s): Psilocybin Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: EB-373
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
EVM301 Series of compounds through lead generation and candidate characterization efforts as it aims to develop compounds that engage the serotonin 5HT2a receptor and the potential treatments for mental health disorders.
Lead Product(s): EVM301
Therapeutic Area: Psychiatry/Psychology Product Name: EVM301
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
